LOX-1和CX3CR1与冠状动脉狭窄性疾病关系及其预后价值的探讨  

Association of LOX-1 and CX3CR1 with coronary artery stenosis disease and its outcomes

作　　者：刘军锋[1] 李旭[2] 贾克刚[1] 李永姝[1] 韩雪晶[1] 刘运德[3] 

机构地区：[1]天津泰达国际心血管病医院天津医科大学心血管病临床学院检验科,300457 [2]天津市环湖医院检验科 [3]天津医科大学医学检验学院

出　　处：《中华检验医学杂志》2014年第1期66-71,共6页Chinese Journal of Laboratory Medicine

基　　金：基金项目：天津市自然科学基金面上项目资助课题（12JCYBJC17400）;天津市卫生行业重点攻关项目资助课题（12KG139）;滨海新区医药卫生科技重点项目资助课题（2011BHKZ003）;天津市卫生局科技基金资助课题（2012KZ008）;泰达国际心血管病医院科研基金资助课题（TD-2012-03）

摘　　要：目的探讨血凝素样氧化低密度脂蛋白（OX—LDL）受体-1（LOX-1）、CX3C趋化因子受体1（CX3CR1）与冠状动脉狭窄性疾病关系及其预后价值。方法临床病例对照研究。选取天津泰达国际心血管病医院心内科2011年5月至2013年4月收治的176例冠状动脉狭窄性疾病患者，均经冠状动脉造影（CAG）确认（冠状动脉血管狭窄达到或超过50％）。对照组为同期本院经CAG证实无冠状动脉病变的非冠心病的患者，均排除心脏疾病，肝、肾功能不全，脑部疾病，血液系统疾病以及其他导致动脉粥样硬化及栓塞类疾病。记录两组的-般资料及实验室指标，检测LOX-1、CX3CR1、尿酸（UA）、肌酐（CREA）。对各组检测指标进行比较，对病例组中单支病变与多支病变LOX—1、CX3CR1进行比较，对LOXtCX3CR1与Gensini积分及各变量进行相关分析。对随访1．5年发生主要心脏不良事件（MACE）组与无MACE组的LOX-1、CX3CR1进行比较，同时比较不同LOX-1、CX3CR1水平患者随访1．5年的MACE。采用SPSS16．0软件进行统计分析。运用独立样本t检验，Mann—WhitneyU检验，，检验，Spearman相关分析，Logistic回归分析，Kaplan—Meier概率对数据进行分析。结果病例组与对照组比较，LOX—1分别为：3．72（1．44，8．15）μg/L与0．75（0．50，1．19）μg／L，z=11．072，P〈0．001；CX3CR1分别为：（2．82±1．85）μg／L与（2．32±0．79）μg／L，t=2．021，P〈0．05：UA分别为：（351．34±94．82）μmo1／L与（326．74±79．51）μmo]／L，t=2．094，P〈0．05；CttEA分别为：（70．86±20．94）μmo1／L与（65．55±12．96）μmo1／L，t=2．077，P〈0．05。多支病变患者CX3CR1水平（2．84±1．78）μg／L明显高于单支病变患者（2．48±1．64）μg/L，差异有统计学意义（t=2．207，P〈0．05）。LOX-1、CX3CR1与Gensini积分均无相关性（尺分别为0．032、0．079，P均〉0．05）。LOX-1�Objective To explore the association of lectin-like oxidized low-density lipoprotein （ox- LDL） receptor -1 （LOX-1） , CX3C ehemokine receptor 1 （CX3CR1） with coronary artery stenosis disease and its outcomes. Methods A ease-control study was conducted. A total of 176 eases of coronary artery stenosis which were confirmed coronary artery stenosis ≥ 50% by coronary angiography（CAG） were served as ease group from department of cardiology of TEDA International Cardiovascular Hospital of Tianjin from May 2011 to April 2013. A total of 129 patients without coronary artery lesion by CAG from this hospital in the same period were served as control group, which has no history of heart disease, liver and kidney dysfuction, brain disease, hematological disease, other disorders that could bring out atherosclerosis and thrombosis. General information and laboratory parameters, LOX-I, CX3CR1, uric acid （UA） and ereatinine （CREA） were measured in 2 groups. These parameters of each group were compared ,the levels of LOX-1 and CX3CR1 in one-vessel stenosis were compared than that in multi-vessels stenosis in case group, the correlations between LOX-1, CX3 CR1 and Gensini score and other variables were analyzed. Comparison of the levels of LOX-1 and CX3CR1 between major adverse cardiovascular events （MACEs） group and non- major adverse cardiovascular event （MACE） group was made during follow up 1.5 years. MACEs in patients with different levels of LOX-1 and CX3CR1 were compared during 1.5-year follow up. All of the data were analyzed by SPSS 16. 0 software. The independent-samples T test, Mann-Whitney U test, Chi-square test, Spearman correlation, Binary Logistic Regression and Kaplan-Meier probability were adopted for data analysis. Results Comparison between ease group and control group, LOX-1 ： 3.72 （ 1.44,8. 15 ） μg/L vs 0. 75（0. 50,1.19） μg/L,z = 11. 072,P 〈0. 001 ;CX3CR1 ： （2. 82 ± 1.85） μg/L vs （2. 32 ±0.79） μg/L, t=2.021,P〈0.05;UA：（351.34±94.82） μmol/Lv

关 键 词：冠状动脉狭窄 清道夫受体 E类 受体 趋化因子 预后 

分 类 号：R541.4[医药卫生—心血管疾病]